<DOC>
	<DOCNO>NCT00753636</DOCNO>
	<brief_summary>The objective study establish safety tolerability isradipine , sustain release preparation patient PD . This study logical continuation project complete conducted preparation NIH submission pivotal study efficacy agent neuroprotection PD . This study conduct parallel Dr. Surmeier 's work development preclinical data . The focus work establish correlation dose demonstrate neuroprotective effect animal model dose use clinical practice . Hypothesis 1 : Patients PD able tolerate isradipine across FDA recommend dose range . We expect 10 % attrition due hypotensive effect agent . Hypothesis 2 : Patients PD concomitant stable hypertension able tolerate isradipine provide dose concomitant antihypertensive agent adjust base blood pressure reading .</brief_summary>
	<brief_title>Parkinson 's Disease Isradipine Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Isradipine</mesh_term>
	<mesh_term>Neuroprotective Agents</mesh_term>
	<criteria>1 . Patients idiopathic Parkinson 's disease age 3075 2 . Hoehn Yahr stage &lt; 2.5 3 . PD duration le 5 year 4 . For subject treat PD medication , regimen stable &gt; 1 month prior enrollment 1 . Atypical Parkinsonian syndrome 2 . Patients history stable hypertension treat antihypertensive agent allow provided dos concomitant anti HTN therapy reduced/adjusted study base BP reading . The number concomitant antihypertensive agent exceed two . The dose concomitant antihypertensive agent stable &gt; 1 month 3 . Presence orthostatic hypotension screen visit define &gt; 20 mmHg change systolic BP 10mm change diastolic BP 2 min standing , baseline BP &lt; 90/60 . 4 . Presence medical condition opinion investigator preclude safe use drug . 5 . Presence cognitive dysfunction determine MMSE score &lt; 24 6 . Failure sign inform consent 7 . Inability cooperate study procedures 8 . Presence motor fluctuation 9 . History bradycardia define heart rate &lt; 55 10 . Women childbearing potential surgically sterilize use reliable measure contraception negative urine pregnancy test screen 11 . Participation investigational drug trial within 30 day prior screen 12 . History brain surgery Parkinson 's Disease .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Isradipine</keyword>
	<keyword>Neuroprotection</keyword>
</DOC>